Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

Core Insights - Esperion Therapeutics reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, and a decline from earnings of $0.34 per share a year ago, indicating an earnings surprise of -16.67% [1] - The company generated revenues of $65 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 12.58%, but down from $137.74 million year-over-year [2] - Esperion's shares have declined approximately 52.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] Earnings Outlook - The future performance of Esperion's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [4][5] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $64.91 million, and for the current fiscal year, it is -$0.09 on revenues of $338.51 million [7] Industry Context - The Medical - Drugs industry, to which Esperion belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Metagenomi, is expected to report a quarterly loss of $0.62 per share, reflecting a year-over-year change of +47.9%, with revenues anticipated to be $8.75 million, down 21.6% from the previous year [9]